PolyCore Therapeutics, Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

PHILADELPHIA, Pa, August 1, 2023 – PolyCore Therapeutics, Inc. today announced that its Board of Directors has determined that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets.


Over the past 16 months, the Company has been advancing its lead compound, PCT-3012, a biased D3 receptor agonist, through IND-enabling studies. A significant amount of work has been accomplished, including metabolite identification and profiling, pharmacokinetics (PK) studies, toxicology studies, and a non-human primate (NHP) efficacy study.  Unfortunately, the pivotal proof of concept study in non-human primates failed to reach significance in the key endpoints.


“We are disappointed in the results of our NHP efficacy study. After extensive and careful review of the data, it is clear that continued development of PCT-3012 for Parkinson’s disease (PD) is not feasible. The Board of Directors unanimously agreed to dissolve and liquidate the Company,” stated Kelly Beck, Chief Executive Officer. “We know this is disheartening for Parkinson’s patients and their families as there continues to be an unmet medical need in addressing the symptoms of PD, especially dyskinesias which are a side effect of current medications.”